Literature DB >> 11499636

Viral infections of the CNS with special emphasis on herpes simplex infections.

E Schmutzhard1.   

Abstract

Within the past decade the management of acute HSV I encephalitis has been improved dramatically by the advent of the polymerase chain reaction (PCR), a method which has become the gold standard of diagnosis of HSV I encephalitis, replacing diagnostic uncertainties and, avoiding, in particular, invasive brain biopsy. Early detection of HSV II in the neonate is mandatory; however, prevention by Caesarean section and/or prenatal therapy of the mother are for this the best option. Very recently the causative agent of Mollaret's meningitis has proved to be, at least in part, HSV I or II. So far prospective randomized therapeutic trials are awaited for the treatment of Mollaret's meningitis using intravenous acyclovir or the more modern oral forms of virostatics (famciclovir, valaciclovir). For decades the causative agent of facial palsy (Bell's palsy) has been sought; only with the advent of PCR has this question been answered. Although one single study indicates the superiority of a combination of acyclovir plus prednisone, this finding has to be confirmed by a large scale prospective randomised double blind study. Nevertheless, if other causes for the clinical/neurological syndrome of peripheral facial palsy have been excluded, a combination therapy with acyclovir plus prednisone seems to be indicated in a patient with Bell's palsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499636      PMCID: PMC7088172          DOI: 10.1007/s004150170155

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort.

Authors:  Vishwajit L Nimgaonkar; Robert H Yolken; Tianxiu Wang; Chung-Chou H Chang; Lora McClain; Eric McDade; Beth E Snitz; Mary Ganguli
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

Review 2.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 3.  [Inflammatory lesions of the brainstem and the cerebellopontine angle].

Authors:  J Lutz; L Jäger
Journal:  Radiologe       Date:  2006-03       Impact factor: 0.635

4.  In-hospital herpes simplex encephalitis after open heart surgery: an emerging pathology or an under-recognised condition?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2013-07-10

Review 5.  [Acute viral and emerging viral CNS infections].

Authors:  S Menon; T Lenhard; U Meyding-Lamadé
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

6.  Simultaneous detection of herpes simplex virus 1 and 2 in the cerebrospinal fluid of a patient with seizures and encephalitis.

Authors:  Neil W Anderson; William Sistrunk; Matthew J Binnicker
Journal:  J Clin Microbiol       Date:  2014-10-29       Impact factor: 5.948

Review 7.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

8.  APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells.

Authors:  Giovanna De Chiara; Maria Elena Marcocci; Livia Civitelli; Rafaela Argnani; Roberto Piacentini; Cristian Ripoli; Roberto Manservigi; Claudio Grassi; Enrico Garaci; Anna Teresa Palamara
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 9.  [Symptomatic headache. Essential differential diagnosis].

Authors:  S Förderreuther
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

10.  Etiology of encephalitis in Australia, 1990-2007.

Authors:  Clare Huppatz; David N Durrheim; Christopher Levi; Craig Dalton; David Williams; Mark S Clements; Paul M Kelly
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.